Premium
Clinical utility of urinary soluble F as in screening for bladder cancer
Author(s) -
Srivastava Anupam Kumar,
Singh Pankaj Kumar,
Singh Dhramveer,
Dalela Divakar,
Rath Srikanta Kumar,
Bhatt Madan Lal Brahma
Publication year - 2016
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12165
Subject(s) - urinary system , medicine , urology , cystoscopy , cytology , urine cytology , urinary bladder , bladder cancer , biomarker , urine , cancer , transitional cell carcinoma , malignancy , gastroenterology , oncology , pathology , biology , biochemistry
Aim Early diagnosis of carcinoma of urinary bladder remains a challenge. Urine cytology, as an adjunct to cystoscopy, is less sensitive for low‐grade tumors. Soluble F as ( sFas ), a cell‐surface receptor and member of the tumor necrosis factor superfamily, is frequently expressed in urinary bladder carcinoma. The objective of this study was to investigate the urinary sFas for diagnosis of transitional cell carcinoma ( TCC ) of urinary bladder. Methods We examined urinary s Fas concentration in 74 controls and 117 cases of TCC , both primary and recurrent disease, by using enzyme‐linked immunosorbent assay and compared it with urinary cytology. Result Urinary s Fas concentration was found to be significantly higher in the patient as compared to control group ( P < 0.05). An optimal cutoff value of 174.0 pg/mL was proposed. The urinary sFas level was found to have an approximate sensitivity and specificity of 88.03% and 89.19% ( P < 0.001), whereas urine cytology had sensitivity of 66.67% and specificity of 95.95%. sFas had better sensitivity in higher grade and both primary and recurrent cases of urinary bladder cancer in comparison with cytology. Out of 15 node positive bladder cancer cases, 13 had high urinary sFas levels, whereas 12 were urinary cytology positive for malignancy. Conclusion Urinary sFas can be used as a non‐invasive diagnostic biomarker for TCC of urinary bladder, both for primary and recurrent disease.